← Back to Stock Screener← Stock Screener

ZYBERNO

Stock Report

Updated Sep 1, 2026

CytomX Therapeutics, Inc. (CTMX)

Healthcare • NASDAQ

$3.21

Professional Investment Analysis

ZYBERNO SCORE →

Is it a great business? Is it getting better?

36.0/100

WEAK BUSINESS

CytomX Therapeutics, Inc. (CTMX) scores 36/100 — weak fundamentals with mixed indicators requiring careful analysis before acting.

📊 How is the Zyberno Score calculated? +

The Zyberno Score answers one question: "Is this a quality business worth owning?" It's a 0-100 investment grade that evaluates business fundamentals across four critical dimensions, based on principles from Warren Buffett, Benjamin Graham, Peter Lynch, and Charlie Munger.

The 4 Core Categories (25 points each):

1. PROFITABILITY (25 pts)

Metrics: ROE, ROIC, Net Margin, Operating Margin
Thresholds: ROE >20% excellent • ROIC >20% excellent • Net Margin >20% excellent • Operating Margin >25% excellent

2. FINANCIAL STRENGTH (25 pts)

Metrics: Debt-to-Equity, Current Ratio, Interest Coverage, Altman Z-Score
Thresholds: D/E <0.3 excellent • Current Ratio >2.5 excellent • Interest Coverage >10x excellent • Altman Z >3.0 safe

3. CASH FLOW QUALITY (25 pts)

Metrics: Free Cash Flow, OCF vs Net Income, FCF Margin
Thresholds: Positive & growing FCF excellent • OCF/NI >1.2x excellent (cash earnings exceed accounting)

4. GROWTH & CONSISTENCY (25 pts)

Metrics: Revenue Growth, Net Income Growth, FCF Growth, Piotroski F-Score
Thresholds: Growth via log-linear regression • Piotroski 8-9 excellent, 6-7 good

Score Interpretation:

75-100

GREAT BUSINESS

65-74

GOOD BUSINESS

50-64

AVERAGE BUSINESS

30-49

WEAK BUSINESS

0-29

POOR BUSINESS

→ View full CTMX quality analysis & detailed breakdown

VALUATION SIGNAL

N/A (Requires more data)

Requires fair value calculation and current price data

💰 How is Margin of Safety calculated? +

Margin of Safety measures how much discount or premium you're paying relative to a stock's intrinsic value. It's Benjamin Graham's core principle: the larger the margin, the lower your downside risk.

Formula: (Intrinsic Value − Current Price) ÷ Intrinsic Value × 100%

How We Calculate Intrinsic Value (DCF Method):

Step 1: Calculate current Owner Earnings (OCF − Maintenance CapEx)

Step 2: Calculate company-specific growth rate using log-linear regression on 16 quarters of Owner Earnings

Step 3: Project 10 years forward using the calculated growth rate

Step 4: Discount each year's cash flow to present value using 10% discount rate

Step 5: Calculate terminal value using 3% perpetual growth rate

Step 6: Sum all discounted cash flows = Intrinsic Value

What The Percentages Mean:

+50% or more

EXCELLENT — Very undervalued

+25% to +50%

GOOD — Attractive discount

0% to +25%

FAIR — Reasonable value

0% to -25%

CAUTION — Slight premium

-25% or worse

POOR — Overvalued

"Price is what you pay, value is what you get." — Warren Buffett

→ View full CTMX valuation analysis · → View full CTMX Brina Gap analysis

📈 How is Brina Gap calculated? +

Brina Gap measures the difference between the growth a business can fundamentally sustain and the growth the market is already pricing in.

Formula: Fundamental Growth Rate − Market-Implied Growth Rate

The Two Components:

Fundamental Growth Rate = ROIC × Reinvestment Rate

What the business can sustainably grow at based on how much it reinvests and what return it earns on that capital. Grounded in historical financials.

Market-Implied Growth Rate = Reverse DCF

The growth rate the current Enterprise Value implicitly assumes. Calculated by back-solving a 10-year DCF model (10% WACC, 3% terminal growth) until the present value of projected cash flows equals EV.

What The Gap Means:

Gap > +5% Market Underestimates — potential upside

+2% to +5% Slight Underestimate

-2% to +2% Fairly Priced — market consensus matches fundamentals

-5% to -2% Slight Overestimate

Gap < -5% Market Overestimates — price embeds optimism fundamentals don't support

A positive gap (market underestimates) combined with a positive Margin of Safety is the strongest combined signal — the business is both cheap historically and forward economics are stronger than the price suggests.

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-38.5%)

Debt-to-Equity (Solvency Risk):EXCELLENT (0.08x)

Operating Margin (Operational Efficiency):CRITICAL (-326.4%)

Return on Capital (Capital Efficiency):CRITICAL (-22.5%)

📊 Valuation Trilogy

Three interconnected metrics for complete valuation analysis

Click any metric for full methodology and detailed analysis

Zyberno's Verdict

CytomX Therapeutics, Inc. (CTMX) stock report — Zyberno Score 36/100 (WEAK BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, CTMX generated -$80.19M in Owner Earnings. Capital was deployed as follows: $101.00K invested in capital expenditures. Reinvestment rate: 1.5%.

DIVISION I: EXECUTIVE SUMMARY

A. Market Valuation

Market Price & Capitalization (2)

Current Price:3.21

Market Cap:$702.80M

Valuation Multiples (3)

P/B Ratio:2.33x

P/S Ratio:26.32x

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$691.28M

Price Action & Momentum (3)

12-1 Momentum:

+57.4% (86th pctile)

📈 Click to view full CTMX Momentum analysis →

Momentum Percentile:86 / 100

% of 52-Week High:39.1%

B. Profitability Assessment

Return Metrics (5)

ROE:

-38.5%

📊 Click to view full CTMX ROE analysis →

ROA:-30.3%

Roic:

-22.5%

📊 Click to view full CTMX ROIC analysis →

Reinvestment Rate:1.5%

Fundamental Growth Rate (g):-0.3%

Margin Analysis (3)

Operating Margin Ttm:-326.4%

Net Margin Ttm:-298.3%

Ebitda Margin:-320.5%

TTM Performance (2)

Operating Margin Ttm:-326.4%

Net Margin Ttm:-298.3%

Yield Metrics (2)

Earnings Yield:-$19.00

Dividend Yield:0.0%

C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

Earnings Surprise (SUE):

-0.32

📊 Click to view full CTMX Earnings Surprise analysis →

EPS Surprise vs Expected:-460.0%

Latest Earnings Filed:2026-08-06

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-28.5%

Earnings Growth (Linear) (1)

Net Income Growth Rate (Linear):100.0%

Operating Growth (Linear) (1)

Operating Income Growth Rate (Linear):100.0%

D. Financial Stability

Liquidity Ratios (3)

Current Ratio:9.36x

Quick Ratio:9.36x

Cash Ratio:0.43x

Leverage Analysis (3)

Debt To Equity Ttm:0.08x

Debt-to-Equity Ratio:0.08x

Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:333,294,000.00

Cash And Cash Equivalents:17,224,000.00

Long Term Debt:$4.21M

Net Debt:-$11.52M

DIVISION II: FINANCIAL STATEMENTS ANALYSIS

A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $26.70M

Linear Growth: -28.5%

📊 Click to view full CTMX Revenue analysis & methodology →

Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00

Operating income TTM: -$87.15M

Linear Growth: 100.0%

📊 Click to view full CTMX Operating Income analysis & methodology →

Bottom Line Performance (3)

Net income TTM: -$79.65M

Linear Growth: 100.0%

📊 Click to view full CTMX Net Income analysis & methodology →

Income Before Tax:-$79.42M

Ebitda Ttm:-85,587,000.00

Operating Expenses (5)

Operating Expenses:105,454,000.00

R And D Expense:73,374,000.00

Sga Expense:32,080,000.00

Income Tax Expense:$232.00K

Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:5,174.5%

Sga To Revenue Percentage:2,262.3%

Ebitda Margin:-320.5%

B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$381.23M

Current Assets:$373.16M

Ppe Net:1,079,000.00

Goodwill:949,000.00

Intangible Assets:$365.00K

Liability Structure (4)

Total Liabilities:79,158,000.00

Current Liabilities:39,861,000.00

Long Term Debt:$4.21M

Short Term Debt:$1.50M

Equity & Capital (3)

Equity:$302.07M

Retained Earnings:-$750.86M

Common Stock:2,000.00

Working Capital Items (3)

Accounts Receivable:37,494,000.00

Inventory:0.00

Accounts Payable:12,353,000.00

Special Items (2)

Contract Liabilities:54,690,000.00

Stock Based Compensation:4,706,000.00

C. Cash Flow Analysis

Operating Activities (2)

-$80.09M-$80.19M

Investment Activities (2)

Investing Cash Flow:-$192.78M

Capital Expenditures Ttm:101,000.00

Financing Activities (3)

Financing Cash Flow:$234.49M

Dividends Paid Ttm:0.00

Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:228,351,000.00

Long Term Debt Issuance:$0.00

Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:1,565,000.00

DIVISION III: OPERATIONAL METRICS

A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.61

Eps diluted TTM: -$0.61

Linear Growth: 100.0%

📊 Click to view full CTMX EPS analysis & methodology →

Earnings Per Share Ttm:-$0.36

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.12

Operating Cash Flow Per Share:-$0.35

Book Value & Capital (2)

Book Value Per Share:$1.38

Cash Per Share:0.08

Dividend Policy (1)

Dividend Payout Ratio:-999.00x

B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.10x

Working Capital Turnover Ttm:0.08x

Receivables Management (2)

Receivables Turnover Ttm:0.71x

Days Sales Outstanding Ttm:512.52

Inventory Management (2)

Inventory Turnover Ttm:-999.00x

Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:168.86

Cash Conversion Cycle:-655.34

C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00

Quality Score:40.00

Market Metrics (2)

Beta:0.00x

Volatility Category:unknown

DIVISION IV: INVESTMENT ANALYSIS

A. Value Investment Framework

Owner Earnings Analysis (1)

-$80.19M

Damodaran Growth Analysis (2)

Reinvestment Rate:1.5%

Fundamental Growth Rate (g):-0.3%

B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (3)

Revenue Growth Rate (Linear):-28.5%

Net Income Growth Rate (Linear):100.0%

Operating Income Growth Rate (Linear):100.0%

Other Growth Rates (1)

Book Value Growth Rate (Linear):41.1%

C. Company Profile & Context

Corporate Information (6)

Symbol:CTMX

Company Name:CytomX Therapeutics, Inc.

Sector:Healthcare

Industry:Pharmaceuticals

Exchange:NASDAQ

Country:United States

Market Classification (3)

Market Cap Category:N/A

Price Category:low

Volume Category:N/A

Share Structure (3)

Shares Outstanding:218.94M

Shares Outstanding Basic:218.94M

Shares Outstanding Diluted:218.94M

Data Processing Info (3)

Processing Version:v3.0

Last Updated:2026-09-01 16:20:17 UTC

Data Timestamp:2026-09-01T16:20:17.866148